Study: NCT04903093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib Suspension F1
Description: Single dose of abrocitinib 200 mg oral suspension formulation 1 will be administered after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib Suspension F1
Description: Single dose of abrocitinib 200 mg oral suspension formulation 1 will be administered after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib Suspension F2
Description: Single dose of abrocitinib 200 mg oral suspension formulation 2 will be administered after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib Suspension F2
Description: Single dose of abrocitinib 200 mg oral suspension formulation 2 will be administered after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib Suspension F3
Description: Single dose of abrocitinib 200 mg oral suspension formulation 3 will be administered after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib Suspension F3
Description: Single dose of abrocitinib 200 mg oral suspension formulation 3 will be administered after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib Suspension F4
Description: Single dose of abrocitinib 200 mg oral suspension formulation 4 will be administered after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib Suspension F4
Description: Single dose of abrocitinib 200 mg oral suspension formulation 4 will be administered after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib Suspension F5
Description: Single dose of abrocitinib 200 mg oral suspension formulation 5 will be administered after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib Suspension F5
Description: Single dose of abrocitinib 200 mg oral suspension formulation 5 will be administered after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib Suspension F6
Description: Single dose of abrocitinib 200 mg oral suspension formulation 6 will be administered after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abrocitinib Suspension F6
Description: Single dose of abrocitinib 200 mg oral suspension formulation 6 will be administered after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.